Tag: Humacyte

Ukrainian surgeons present clinical update on Human Acellular Vessel in vascular...

Humacyte recently announced the presentation of a clinical update on the Human Acellular Vessel (HAV) for the treatment of vascular trauma. The update was...
vascular trauma

Humacyte provides update on patients treated at front-line hospitals in Ukraine...

Humacyte today announced that the first Ukrainian patients have received implants of the Human Acellular Vessel (HAV) for the treatment of vascular trauma injuries....
vascular trauma

Humacyte’s Human Acellular Vessel for limb salvage evaluated in multiple complex...

Humacyte today announced results from the first series of compassionate use cases of the company’s investigational Human Acellular Vessel (HAV) for the treatment of...
vascular trauma

Humacyte to present long-term follow-up data from Phase 2 vascular access...

Humacyte has announced that the clinical results of five-year outcomes in patients receiving the human acellular vessels (HAV) for arteriovenous (AV) access in haemodialysis...

Humacyte commences phase II vascular trauma trial

Humacyte has announced the initiation of a US phase II vascular trauma clinical trial of Humacyl, its investigational human acellular vessel, for vascular replacement...

Humacyte appoints Doug Blankenship as chief financial officer

Humacyte has announced the appointment of Douglas L Blankenship as chief financial officer, effective Monday, 8 October, 2018. According to a company release, Blankenship is...

Humacyte appoints Jeffrey Lawson as president and CEO

Humacyte, an innovator in biotechnology and regenerative medicine, has announced that Jeffrey Lawson has been appointed president and chief executive officer. The former chairman...

Fresenius and Humacyte enter strategic global partnership with US$150M equity investment

Fresenius Medical Care, the world's largest provider of dialysis products and services, and Humacyte, Inc., a medical research, discovery and development company, have announced...

Humacyte’s Humacyl receives US FDA expedited review designation

The US Food and Drug Administration (FDA) has granted Humacyte’s Humacyl investigational human acellular vessel (HAV) Regenerative Medicine Advanced Therapy (RMAT) designation. This designation means...

Humacyte commences US phase II arterial bypass clinical trial

Humacyte has announced the initiation of a US phase II arterial bypass clinical trial of Humacyl, an investigational human acellular vessel, to test its safety...